Tag: medicines

Workshop on regulatory support for development of orphan medicines

On Monday, 30 November, EMA is hosting a workshop to discuss the benefits and impact of early regulatory interactions and incentives for the development of medicines for rare diseases.

The purpose of the workshop is to encourage early dialogue between developers and regulators in order to facilitate the development of innovative medicines in neglected disease areas. The workshop is targeted at small and medium-sized enterprises (SMEs), academia, patients, healthcare professionals and European Reference Networks (ERNs) who are often at the forefront of medicine development in rare and neglected diseases.

There are over 6,000 rare diseases that affect about 30 million

Read More